These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 25809304)

  • 1. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
    Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L
    Neurology; 2015 Apr; 84(16):1639-43. PubMed ID: 25809304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
    Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
    Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Montalban X; Comi G; O'Connor P; Gold S; de Vera A; Eckert B; Kappos L
    Mult Scler; 2011 Nov; 17(11):1341-50. PubMed ID: 21727148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?
    Bielekova B; McDermott MP
    Neurology; 2015 Apr; 84(16):1620-1. PubMed ID: 25809305
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
    N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
    Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
    Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
    Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
    Kuhle J; Kropshofer H; Haering DA; Kundu U; Meinert R; Barro C; Dahlke F; Tomic D; Leppert D; Kappos L
    Neurology; 2019 Mar; 92(10):e1007-e1015. PubMed ID: 30737333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fingolimod in relapsing-remitting multiple sclerosis.
    Sorensen PS
    Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N; Kim E
    Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
    [No Abstract]   [Full Text] [Related]  

  • 20. [The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
    Kotov SV; Fedorova SI; Iakushina TI; Lizhdvoĭ VIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):74-8. PubMed ID: 23528598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.